| 2026-08-19 | Press release | Monopar Appoints Jeffrey D. Kent, M.D., as Executive Vice President, Head of Medical Affairs; Announces Two ALXN1840 Presentations at AASLD - The Liver Meeting® 2026 |
| 2026-08-12 | Press release | Monopar Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates |
| 2026-08-12 | 8-K | Form 8-K, Item 2.02 results |
| 2026-08-12 | 10-Q | Form 10-Q for the quarter ended Jun 30 |
| 2026-07-22 | Press release | Monopar Initiates Rolling NDA Submission for ALXN1840 in Wilson Disease |
| 2026-07-22 | 8-K | Form 8-K, Item 7.01 |
| 2026-07-20 | Press release | Monopar Advances Launch Readiness with Addition of Veteran Commercial Executive Nicole Sweeny to Board of Directors and |
| 2026-06-30 | Press release | Monopar Therapeutics Receives FDA Rare Pediatric Disease Designation for ALXN1840 for the Treatment of Wilson Disease |
| 2026-06-30 | 8-K | Form 8-K, Item 7.01 |
| 2026-06-26 | Press release | Monopar Presents New Analyses of Phase 3 FoCus Data at EAN 2026 Showing Greater Neurologic and Global Clinical Benefit w |
| 2026-06-26 | 8-K | Form 8-K, Item 7.01 |
| 2026-06-23 | 8-K | Form 8-K, Item 5.07 |
| 2026-06-01 | Press release | Monopar Presents Phase 2 ALXN1840 Data Demonstrating Liver Disease Stabilization and Neurologic Improvement in Treatment |
| 2026-05-29 | 8-K | Form 8-K, Item 7.01 |
| 2026-05-19 | Press release | Monopar Announces Publication of Phase 2 Study Demonstrating ALXN1840 Significantly Improves Copper Balance in Patients |
| 2026-05-19 | 8-K | Form 8-K, Item 7.01 |
| 2026-05-14 | Press release | Monopar Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates |
| 2026-05-14 | Press release | Monopar Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates |
| 2026-05-14 | Press release | PDF |
| 2026-05-14 | 8-K | Form 8-K, Item 2.02 results |
| 2026-05-14 | 10-Q | Form 10-Q for the quarter ended Mar 31 |
| 2026-04-30 | Proxy | Definitive proxy statement |
| 2026-04-20 | 8-K | Form 8-K, Item 7.01 |
| 2026-04-19 | Press release | Monopar Presents Phase 3 Data Showing Greater Neurologic Benefit with ALXN1840 vs SoC in Wilson Disease Patients with Ne |
| 2026-04-01 | 10-K | Annual report on Form 10-K/A, FY25 |
| 2026-03-27 | Press release | Monopar Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Business Update |
| 2026-03-27 | 8-K | Form 8-K, Item 2.02 results |
| 2026-03-27 | 10-K | Annual report on Form 10-K, FY25 |
| 2026-03-16 | Deck | https://d1io3yog0oux5.cloudfront.net/_46c180b00471d92f154cbd1d20ad5d2c/monopartx/db/354/2994/pdf/MNPR+Corporate+Presentation+Mar+2026.pdf |
| 2026-03-02 | Press release | Monopar Expands Leadership Team with Appointment of Seasoned Biopharma Executive Susan Rodriguez as Chief Commercial and |
| 2026-03-02 | 8-K | Form 8-K, Item 7.01 |
| 2025-11-13 | Press release | Monopar Therapeutics Reports Third Quarter 2025 Financial Results and Recent Developments |
| 2025-11-13 | 8-K | Form 8-K, Item 2.02 results |
| 2025-11-13 | 10-Q | Form 10-Q for the quarter ended Sep 30 |
| 2025-11-10 | 8-K | Form 8-K, Item 7.01 |
| 2025-11-09 | Press release | Monopar Presents New Data and Analyses on Rapidly Improved Copper Balance in Wilson Disease Patients on Tiomolybdate Cho |
| 2025-10-15 | Press release | Monopar Announces Abstract Accepted for Oral Presentation at AASLD - The Liver Meeting® 2025 |
| 2025-09-24 | 8-K | Form 8-K, Item 1.01 |
| 2025-09-23 | Press release | Monopar Therapeutics Inc. Announces Pricing of $135 Million Underwritten Offering of Common Stock and Pre-Funded Warrant |
| 2025-09-23 | Press release | Monopar Announces Journal of Hepatology Publishes Physicians’ Letter to the Editor Demonstrating ALXN1840 Rapidly Improv |